Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DXS0 | ISIN: US17322U2078 | Ticker-Symbol: 47N
Tradegate
28.03.24
18:03 Uhr
0,844 Euro
+0,088
+11,57 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
CITIUS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
CITIUS PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,8100,85123:00
0,8050,85222:00

Aktuelle News zur CITIUS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.03.Citius Pharmaceuticals receives FDA acceptance of resubmission for its relapsed lymphoma treatment1
18.03.Citius Pharmaceuticals Announces Acceptance Of BLA Resubmission For LYMPHIR1
18.03.Citius Pharma's LYMPHIR BLA accepted by FDA, decision by August 132
18.03.Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma85FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of August 13, 2024 CRANFORD, N.J., March 18, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq:...
► Artikel lesen
13.03.Citius Pharmaceuticals, Inc. - 8-K, Current Report4
07.03.Citius aims to bounce back from Lymphir setback3
07.03.Citius Pharmaceuticals to receive $2.4 million in NJ funding2
07.03.Citius Pharmaceuticals Receives $2.4M Through NJ Economic Development Program2
26.02.Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration161CRANFORD, N.J., Feb. 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization...
► Artikel lesen
23.02.Citius Pharmaceuticals files for $250M mixed securities shelf4
23.02.Citius Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans2
15.02.Citius Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary4
14.02.Citius Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
14.02.Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update224Resubmitted LYMPHIR Biologics License Application; awaiting PDUFA date Completed enrollment in the Mino-Lok® Pivotal Phase 3 trial CRANFORD, N.J., Feb. 14, 2024 /PRNewswire/ -- Citius Pharmaceuticals...
► Artikel lesen
14.02.Citius Pharma Resubmits BLA Of Lymphir To FDA2
14.02.Citius Pharmaceuticals, Inc. - 8-K, Current Report1
14.02.Citius Pharmaceuticals, Inc.: Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma151FDA acceptance of the completed resubmission package and issuance of a Prescription Drug User Fee Act (PDUFA) date is expected within 30 days of resubmission CRANFORD, N.J., Feb. 13, 2024 /PRNewswire/...
► Artikel lesen
23.01.Citius Pharmaceuticals, Inc. - 8-K, Current Report6
09.01.TenX Keane Asks for up to 10 More Months to Finalize Citius Oncology Deal8
02.01.Citius Pharmaceuticals, Inc. - 8-K, Current Report3
Seite:  Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1